

# EXPLORE THE EVIDENCE FOR RDN

The Medtronic Symplicity Spyrals™ Renal Denervation (RDN) system offers a complementary way to lower patients' blood pressure as shown in sham-controlled clinical trials.<sup>1,2</sup>

## SPYRAL HTN-ON MED PILOT STUDY

9.4 ↓

mmHg Office SBP  
at six months.\*<sup>1</sup>

## SPYRAL HTN-OFF MED PIVOTAL TRIAL

9.2 ↓

mmHg Office SBP  
at three months.\*<sup>†1</sup>



## RECOMMEND RDN TODAY

\*RDN arm reduction from baseline.

†ANCOVA adjusted; secondary efficacy analysis.

1. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *Lancet*. 2018 Jun 9;391(10137):2346-2355.

2. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *Lancet* 2020; Published online March 29, 2020. DOI:10.1016/S0140-6736(20)30554-7.

UC202107939 ML ©2021. Medtronic. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. For distribution only in markets where the Symplicity Spyrals™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan, or France. 03/2021

**Medtronic**

# Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF)

Sana Ouali MD<sup>1</sup>  | Afef Ben Halima MD<sup>2</sup> | Sonia Chabrak MD<sup>3</sup> | Rafik Chettaoui MD<sup>4</sup> | Manel Ben Halima MD<sup>1</sup> | Abdeddayem Haggui MD<sup>5</sup> | Salma Krichane MD<sup>6</sup> | Larbi Nouredine MD<sup>1</sup> | Sonia Marrakchi MD<sup>2</sup> | Selma Charfeddine MD<sup>7</sup> | Majed Hassine MD<sup>8</sup> | Khaled Sayahi MD<sup>9</sup> | Fehmi Abbes Mohamed MD<sup>10</sup> | Wided Nasraoui MD<sup>11</sup> | Hassen Ajmi MD<sup>12</sup> | Mehdi Ben Miled MD<sup>13</sup> | Zeynab Jebbari MD<sup>1</sup> | Mohamed Ali Meghaidh MD<sup>14</sup> | Emna Allouche MD<sup>15</sup> | Rachid Mechmeche MD<sup>3</sup> | Lilia Zakhama MD<sup>16</sup> | Wissem Sdiri MD<sup>17</sup> | Ali Ben Khalfallah MD<sup>18</sup> | Anissa Gharbi MD<sup>19</sup> | Sami Milouchi MD<sup>20</sup> | Ali Neji MD<sup>21</sup> | Saoussen Antit MD<sup>16</sup> | Kais Battikh MD<sup>22</sup> | Meriem Drissa MD<sup>1</sup> | Samira Kaabachi MD<sup>1</sup> | Tarek Najjar MD<sup>23</sup> | Rami Tlili MD<sup>24</sup> | Iheb Chahbani MD<sup>22</sup> | Hanene Charfeddine MD<sup>6</sup> | Mbarek Mohamed Ben MD<sup>25</sup> | Sami Braham MD<sup>26</sup> | Faouzi Maatouk MD<sup>8</sup> | Salem Abdesslem MD<sup>3</sup> | Mokdad Ayari MD<sup>27</sup> | Riadh Garbaa MD<sup>22</sup> | Nabil Hamrouni MD<sup>22</sup> | Dorra Mbarek MD<sup>24</sup> | Hajer Rekik MD<sup>6</sup> | Hamda Zaghoudi MD<sup>4</sup> | Wacef Ayadi MD<sup>6</sup> | Feriel Baraket MD<sup>28</sup> | Karim Ben Brahim MD<sup>4</sup> | Mariem Ben Romdhane MD<sup>19</sup> | Habib Bousadia MD<sup>29</sup> | Wassim Brahim MD<sup>1</sup> | Malek Mezri MD<sup>1</sup> | Ali Guesmi MD<sup>30</sup> | Taha Ounissi MD<sup>31</sup> | Sofiene Kammoun MD<sup>32</sup> | Wajih Smati MD<sup>33</sup> | Samir Tlili MD<sup>34</sup> | Karim Zoughi MD<sup>1</sup> | Jawher Zemni MD<sup>35</sup> | Mahmoud Cheikh Bouhleb MD<sup>1</sup> | Sanaa Islem MD<sup>1</sup> | Rym Jemli MD<sup>1</sup> | Anissa Joulak MD<sup>36</sup> | Khadija Mzoughi MD | Hela Naanea MD<sup>4</sup> | Leila Hached MD<sup>3</sup> | Moufid Hadrich MD<sup>3</sup> | Mohamed Hmem MD<sup>36</sup> | Slim Kacem MD<sup>37</sup> | Ikram Kammoun MD<sup>2</sup> | Rawdha Othmani MD<sup>1</sup> | Amel Ouerghi MD<sup>26</sup> | Syrine Abid MD<sup>36</sup> | Ridha Ennouri MD<sup>38</sup> | Sandrine Haidar MD<sup>19</sup> | Sihem Heraiech MD<sup>4</sup> | Monia Jammali MD<sup>4</sup> | Mourad Jarrar MD<sup>19</sup> | Leila Riahi MD<sup>27</sup> | Basma Trimech MD<sup>19</sup> | Med Ali Azaiez MD<sup>19</sup> | Foued Azzouzi MD<sup>4</sup> | Khaled Ben Jemaa MD<sup>22</sup> | Oussema Ben Rejab MD<sup>39</sup> | Rim Chrigui MD<sup>3</sup> | Wejdene Wechtati MD<sup>15</sup> |

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Clinical Cardiology* published by Wiley Periodicals LLC.

**Essia Boughzela MD<sup>19</sup> | Gouider Jridi MD<sup>39</sup> | Leila Bezdah MD<sup>15</sup> |  
Sondes Kraiem MD<sup>32</sup> | Habiba Drissa MD<sup>1</sup> | Soraya Ben Youssef MD<sup>16</sup> |  
Wafa Fehri MD<sup>5</sup> | Salem Kachboura MD<sup>2</sup> | Habib Gamra MD<sup>8</sup> |  
Samir Kammoun MD<sup>7</sup> | Mohamed Sami Mourali MD<sup>1</sup> | Faouzi Addad MD<sup>2</sup> |  
Leila Abid MD<sup>7</sup>**

<sup>1</sup>Hôpital La Rabta, Tunis, Tunisia

<sup>2</sup>Abderrahman Mami Pneumology and Phthysiology Hospital, Ariana, Tunisia

<sup>3</sup>Pasteur Clinic, Tunis, Tunisia

<sup>4</sup>Manar Clinic, Tunis, Tunisia

<sup>5</sup>Hôpital Militaire Principal d'instruction de Tunis, Tunis, Tunisia

<sup>6</sup>El Alya Clinic, Sfax, Tunisia

<sup>7</sup>Hedi Chaker Hospital, Sfax, Tunisia

<sup>8</sup>Fattouma Bourguiba University Hospital, Monastir, Tunisia

<sup>9</sup>Mhamed Bourguiba Hospital, El Kef, Tunisia

<sup>10</sup>Zaghuan Hospital, Zaghuan, Tunisia

<sup>11</sup>Kasserine Hospital, Kasserine, Tunisia

<sup>12</sup>Habib Bourguiba Hospital, Medenine, Tunisia

<sup>13</sup>Zaghuan Clinic, Zaghuan, Tunisia

<sup>14</sup>Djerba Clinic, Djerba, Tunisia

<sup>15</sup>Charles Nicolle Hospital, Tunis, Tunisia

<sup>16</sup>La Marsa Internal Security Forces Hospital, La Marsa, Tunisia

<sup>17</sup>Bougatfa Hospital, Bizerte, Tunisia

<sup>18</sup>Menzel Bourguiba Hospital, Bizerte, Tunisia

<sup>19</sup>Essalem Clinic, Sousse, Tunisia

<sup>20</sup>Hopital Habib Bourguiba, Medenine, Tunisia

<sup>21</sup>Ben Guerdane Hospital, Medenine, Tunisia

<sup>22</sup>Djerba Clinic, Medenine, Tunisia

<sup>23</sup>Cap Bon Clinic, Nabeul, Tunisia

<sup>24</sup>University Hospital Center Mongi Slim, La Marsa, Tunisia

<sup>25</sup>Kebili Hospital, Kebili, Tunisia

<sup>26</sup>El Amen Clinic, Beja, Tunisia

<sup>27</sup>Cardiovascular Clinic, Tunis, Tunisia

<sup>28</sup>Carthagène Clinic, Tunis, Tunisia

<sup>29</sup>Ezzayatin Clinic, Sousse, Tunisia

<sup>30</sup>Mohamed Ben Sassi Hospital, Gabes, Tunisia

<sup>31</sup>Mohamed Taher Al Maamouri Hospital, Nabeul, Tunisia

<sup>32</sup>Habib Thameur Hospital, Tunis, Tunisia

<sup>33</sup>Hopital Regional de Gafsa, Gafsa, Tunisia

<sup>34</sup>Hédi Jaballah Hospital, Tozeur, Tunisia

<sup>35</sup>Essalem Clinic, Tunis, Tunisia

<sup>36</sup>The Berges of Lac Clinic, Tunis, Tunisia

<sup>37</sup>Carthage Clinic, Monastir, Tunisia

<sup>38</sup>El Alya Polyclinic, Sfax, Tunisia

<sup>39</sup>Farhat Hached University Hospital, Sousse, Tunisia

**Correspondence**

Sana Ouali, Cardiology department, La Rabta Hospital, 1007 La Rabta Jebbari, Tunis, Tunisia.  
Email: sanaouali@hotmail.fr

**Abstract**

**Background:** Contemporary registries on atrial fibrillation (AF) are scarce in North African countries.

**Hypothesis:** In the context of the epidemiological transition, prevalence of valvular AF in Tunisia has decreased and the quality of management is still suboptimal.

**Methods:** NATURE-AF is a prospective Tunisian registry, involving consecutive patients with AF from March 1, 2017 to May 31, 2017, with a one-year follow-up period. All the patients with an Electrocardiogram-documented AF, confirmed in the year prior to enrolment were eligible. The epidemiological characteristics and outcomes were described.

**Results:** A total of 915 patients were included in this study, with a mean age of  $64.3 \pm 22$  years and a male/female sex ratio of 0.93. Valvular AF was identified in 22.4% of the patients. The mean CHA<sub>2</sub>DS<sub>2</sub>VASC score in nonvalvular AF was  $2.4 \pm 1.6$ . Monotherapy with antiplatelet agents was prescribed for 13.8% of the patients. However, 21.7% of the subjects did not receive any antithrombotic agent. Oral anticoagulants were prescribed for half of the patients with a low embolic risk score. In 341 patients, the mean time in therapeutic range was  $48.87 \pm 28.69\%$ . Amiodarone was the most common antiarrhythmic agent used (52.6%). During a 12-month follow-up period, 15 patients (1.64%) had thromboembolism, 53 patients (5.8%) had major hemorrhage, and 52 patients (5.7%) died.

**Conclusions:** NATURE-AF has provided systematic collection of contemporary data regarding the epidemiological and clinical characteristics as well as the management of AF by cardiologists in Tunisia. Valvular AF is still prevalent and the quality of anticoagulation was suboptimal.

**KEYWORDS**

anticoagulation, atrial fibrillation, management, North Africa, outcomes, risk scores

## 1 | INTRODUCTION

In the last decades, a significant change in the epidemiologic and etiologic patterns of cardiovascular diseases has been noted in North African countries, with a decrease in rheumatic heart disease and an increase in hypertensive and ischemic heart diseases.<sup>1,2</sup> A decrease in the incidence of acute rheumatic fever and rheumatic heart disease has also been observed in the last four decades in African countries.<sup>3,4</sup> It is also estimated that by 2050, prevalence of atrial fibrillation (AF) in Africa will be greater than in any other region in the world.<sup>1</sup>

As for all heart diseases, there are insufficient contemporary population-based data, describing the epidemiological and management pattern of AF patients receiving routine medical care in North Africa, especially in Tunisia where rheumatic valvular disease was the most underlying etiology of AF in 2003.<sup>5</sup>

Demographic and prognostic AF data from other ethnic groups, such as European, Asian, and American countries would not be extrapolated to our population. It is unknown whether occidental

studies could be easily applied to low-to-middle income regions, such as North African populations, where reported data are still scarce.

Rheumatic heart disease is present in more than fifth of African AF patients<sup>6-8</sup> compared with 2% in North American AF patients.<sup>9</sup> Anticoagulation prescription rates are low in African AF patients and they have decreased progressively over time. Only 33% of the patients with valvular AF and 12% of those with nonvalvular AF are on anticoagulants at the six-month follow-up.<sup>8</sup>

Thus, a register or a survey dealing with the demographic and prognostic characteristics of AF in Tunisia is essential to be able to identify its specific characteristics inherent partly to the ethnic particularities, but especially to the particularities of the local health system, in the context of the epidemiological and guidelines transitions. Hence, the National Tunisian Registry of Atrial Fibrillation (NATURE-AF) was performed as previously described.<sup>10</sup> The aim of the present registry was to describe the epidemiological characteristics, the quality of management and the outcomes over a 12-month follow up period.

## 2 | METHODS

NATURE-AF is a prospective, observational registry with a 1-year follow-up period. It included consecutive in- and outpatients with AF presenting to cardiologists between March 1, 2017, and May 31, 2017 all over Tunisia. Screening for eligibility was performed at the time of the patients' presentation to a cardiologist (hospital or medical center). A written informed consent was obtained from all the participants. Patients aged 20 years and older and having at least 1 episode of AF recorded on a standard 12-lead electrocardiogram or on 24-h Holter monitoring were officially involved in NATURE-AF. The qualifying episode of AF should have occurred within the previous year, whether it was valvular or nonvalvular AF. Valvular etiology is considered in patients with at least moderate mitral stenosis or prosthetic heart valves. Patients did not need to have AF at the time of enrollment.

The exclusion criteria were AF due to reversible causes (e.g., thyroid disease and pulmonary embolism), including postoperative AF ( $\leq 3$  months), life expectancy less than 12 months, acute coronary syndrome, isolated atrial flutter, mental disorders, and ongoing anticoagulation for reasons other than AF.

The plan was to have one baseline visit and one visit every 3 months over a 1-year period. Enrollment into the registry started on March 1, 2017, with an estimated inclusion period extending up to 3 months. All the patients were followed for 12 months. During this period, all the participants revisited their cardiologists at the usual intervals (3 months), and the patients taking oral anticoagulant therapy consulted (or visited) at least once every month to have their INR measured.

The data collected were analyzed using the Clinical Suite platform (Dacima Software), complying with the international standards, including US Food and Drug Administration 21 Code of Federal Regulations Part 11, US Health Insurance Portability and Accountability Act, International Conference on Harmonization, and Medical Dictionary for Regulatory Activities. The Clinical Suite platform allowed to track the data entered, to check for inconsistencies and missing data, and to schedule the monitoring visits. A steering committee was set up to monitor patients' inclusions, to verify data sources, to perform the audit trail, and to prepare the statistical analysis plan for the study. The steering committee was composed of the arrhythmia working-group of the National Society of Cardiology and Cardiovascular Surgery ([www.stccv.org.tn](http://www.stccv.org.tn)).

Data were collected every 3 months regardless of the patients' clinical follow-up. All incident events and therapeutic changes were entered at each collection interval.

Baseline data included the patients' demographics, medical history, cardiovascular history, details of AF history and therapies, vital signs, laboratory measurements, electrocardiographic data, cardiac imaging parameters, details of medical management, and any contraindications to anticoagulation. CHA<sub>2</sub>DS<sub>2</sub>VASc score (Congestive heart failure history, Hypertension history, Age, Diabetes history, Stroke—thromboembolism history, vascular disease history), HAS-BLED score (Hypertension, Renal disease, Liver disease, stroke history, Prior major

bleeding or disposition to bleeding, age > 65, medication usage predisposing to bleeding, and alcohol use), and SAME-TT2R2 score (Sex, Age, Medical history, Treatment, Tobacco use, Race) were calculated. During the follow-up period, major incidents, events, and procedures were recorded. The INR value was also noted for patients taking acenocoumarol.

The endpoints of NATURE-AF are to describe:

1. the epidemiological characteristics of patients with AF in Tunisia
2. the management features regarding the anticoagulation characteristics and the choice of the rate or rhythm control strategy
3. the outcomes over a 12-month follow-up period: incidence of thromboembolic events, cardiovascular death, and hemorrhagic accidents

### 2.1 | Statistical analysis

The normality of continuous variables was verified with the Shapiro-Wilk test. Continuous variables were described by mean and standard deviation or as median and interquartile range. Categorical variables were described by the size and frequency of every modality. Means comparison was performed by analysis of variance or by nonparametric tests if the hypothesis of normality is rejected. Statistical tests were bilateral with a 95% confidence interval.

A chi-square test was performed for categorical variables. The Yates correction or Fisher exact test was used if the conditions of validity for the chi-square test were not met.

A multivariate analysis was performed with anticoagulant treatment (over or undertreated) as dependent factor. The independent variables were age, gender, body mass index, type of AF, and combined therapy. Univariate logistic regression was carried out with a 10% output threshold. The final model was performed using the parameters selected by the backward stepwise method of Wald. The selected variables in the final model were tested at the 5% threshold. Interaction between the selected parameters was tested at the 10% threshold.

The TTR was calculated as described by Rosendaal et al,<sup>11</sup> using linear interpolation of INR values in each patient under oral anticoagulant treatment to calculate the percentage of days when INR is in the therapeutic range (2.0–3.0) for nonvalvular AF.

## 3 | RESULTS

### 3.1 | Patient characteristics

A total of 915 patients, including 475 (51.9%) women, were involved in NATURE-AF. The mean (SD) age of the patients was 64.27 (22) years. Among the patients, 202 (22.1%) were aged 75 years and older, and 67.8% of them ( $n = 620$ ) were enrolled by public cardiologists. The number of healthcare units involved was 37. A total of eighty-eight cardiologists participated in the study, representing 22%

**TABLE 1** Clinical characteristics and antithrombotic and antiarrhythmic drugs used of the study population

Clinical characteristics	Total (N = 915)	Nonvalvular AF N = 710. (77.6%)	Valvular AF N = 205 (22.4%)	p
Age (years) (mean ± SD)	64.27 ± 22	64.22 ± 22	64.43 ± 24	.846
Sex ratio (male/female)	0.93	1.01	0.69	.022
BMI kg/m <sup>2</sup> (mean ± SD)	27.92 ± 5.06	27.94 ± 5.51	27.85 ± 17.1	.837
Smoking habit (N [%])	159 (17.4%)	139 (19.6%)	20 (9.8%)	.001
Dyslipidemia (N [%])	180 (19.7%)	144 (20.3%)	36 (17.6%)	.426
Hypertension (N [%])	439 (48.0%)	355 (50.0%)	84 (41.0%)	.026
Diabetes mellitus (N [%])	207 (22.6%)	165 (23.2%)	42 (20.5%)	.449
Congestive heart failure (N [%])	116 (12.7%)	91 (12.8%)	25 (12.2%)	.905
Prior stroke/TIA /thromboembolic event (N [%])	78 (8.5%)	57 (8.0%)	21 (10.2%)	.319
Age ≥ 75 years (N [%])	202 (22.1%)	152 (21.4%)	50 (24.4%)	.365
Age ≥ 65 years (N [%])	460 (50.3%)	356 (50.1%)	104 (50.7%)	.937
LVEF (%) (mean ± SD)	58.1 ± 12.3	58.2 ± 12.6	57.4 ± 11.6	.516
Coronary artery disease (N (%))	95 (10.4%)	77 (10.8%)	18 (8.8%)	.393
Prior PCI (N (%))	55 (6%)	47 (6.6%)	8 (3.9%)	.149
Prior CABG (N (%))	16 (1.7%)	12 (1.7%)	4 (2.0%)	.775
Clearance <30 ml (N (%))	13 (1.5%)	9 (1.2%)	4 (2.0%)	.657
Cancer (N (%))	18 (2.0%)	14(2.0%)	4(2.0%)	.977
History of stroke (N (%))	78 (8.5%)	57 (8.0%)	21 (10.2%)	.319
History of bleeding (N (%))	17 (1.9%)	15 (2.1%)	2 (1.0%)	.306
Obstructive sleep apnea (N (%))	26 (2.8%)	19 (2.7%)	7 (3.4%)	.575
Respiratory failure (N (%))	49 (5.5%)	39 (5.5%)	10 (4.9%)	.731
Paroxysmal AF (N (%))	308 (33.7%)	268 (37.7%)	40 (19.5%)	<.001
Persistent AF (N (%))	313 (34.2%)	237 (33.4%)	76 (37.1%)	<.001
Permanent AF (N (%))	206 (22.5%)	140 (19.7%)	66 (32.2%)	<.001
Palpitations (N (%))	529 (57.8%)	417 (58.7%)	112 (54.6%)	.296
Dyspnea (N (%))	358 (39.1%)	280 (39.4%)	78 (38.0%)	.720
Syncope (N (%))	38 (4.2%)	28 (3.9%)	10 (4.9%)	.555
CHA <sub>2</sub> DS <sub>2</sub> VASc score (mean ± SD)		2.4 ± 1.6		
Points 0		87 (12.3%)		
Points 1		143 (20.1%)		
Points ≥ 2 (%)		490 (67.6%)		
HASBLED score ≥ à 3		108 (15.2%)		
Pacemaker/ICD (N (%))	36 (3.9%) /6 (0.7%)	31 (4.4%) /5 (0.7%)	5 (2.4%)/1 (0.5%)	.212/.999
History of Electrical cardioversion	9 (1.0%)	4 (0.6%)	5 (2.4%)	.061
Antiplatelet drugs (n (%))	126 (13.8%)	101 (14.2%)	25 (12.2%)	.457
Anticoagulant drug (n (%))	644 (70.4%)	492 (69.3%)	152 (74.1%)	.180
No antithrombotic drugs (n (%))	199 (21.7%)	163 (23.0%)	36 (17.6%)	.098
Combination therapy of antiplatelet agents and oral anticoagulation, (n (%))	54 (5.9%)	46 (6.5%)	8 (3.9%)	.168
Beta-blockers (n (%))	396 (43.9%)	302 (42.5%)	94 (45.9%)	.398
Digoxin (n (%))	131 (14.3%)	98 (13.8%)	33 (16.1%)	.409
Calcium inhibitors (n (%))	154 (16.8)	119 (16.8%)	35 (17.1%)	.916
Electrical cardioversion (n (%))	3 (0.3%)	0	3 (1.5%)	.022
Amiodarone, (n (%))	481 (52.6%)	387 (54.5%)	94 (45.9%)	.029
Flecainide, (n (%))	80 (8.7%)	65 (9.2%)	15 (7.3%)	.412

(Continues)

**TABLE 1** (Continued)

Clinical characteristics	Total (N = 915)	Nonvalvular AF N = 710. (77.6%)	Valvular AF N = 205 (22.4%)	p
d,l-Sotalol, (n (%))	30 (3.3%)	25 (3.5%)	5 (2.4%)	0.443
TTR % (mean) In 341 patients (37.3%)	48.87 ± 28.69	43.97 ± 27.7 206 patients (60.4%)	56.36 ± 28.55 135 patients (39.6%)	<.001
TTR ≥65% (n (%))	110/341 (32.3%)	47/ 206 (22.8%)	63/135 (46.7%)	<.001
SAMe-TT2R2 score (0–2)		203 (28.6%)		

Abbreviations: AF: atrial fibrillation, BMI: body mass index, CABG: coronary artery bypass graft, CHA<sub>2</sub>DS<sub>2</sub>VASc score: [Congestive heart failure history, Hypertension history, Age, Diabetes history, Stroke – thromboembolism history, vascular disease history], EHRA: The European Heart Rhythm Association, HASBLED score: [Hypertension, Renal disease, Liver disease, stroke history, Prior major bleeding or disposition to bleeding, age > 65, medication usage predisposing to bleeding, alcohol use], ICD: implantable cardioverter defibrillator, LVEF: left ventricle ejection fraction, PCI: percutaneous coronary intervention, SAMe-TT2R2 score: [Sex, Age, Medical history, Treatment, Tabacco use, Race], TTR: time in therapeutic range.

of the total cardiologists in Tunisia. Half of the investigators were in the private sector.

The baseline clinical characteristics of all the registered AF patients are summarized in Table 1.

Among the included patients, 33.7% of them were in paroxysmal AF, 34.2% were in persistent AF, and 22.5% were in permanent AF. Two hundred five patients (22.4%) had valvular atrial fibrillation. No significant age differences were noted in the AF subtypes. Fifty nine percent (59.0%) of the patients were women in the valvular AF group. The paroxysmal type of AF was significantly more frequent in the nonvalvular AF group ( $p < .001$ ). The European Heart Rhythm Association (EHRA) score  $\geq 2$  was identified in 41.6% of the patients. Palpitation and dyspnea were the most frequent symptoms expressed respectively in 57.8% and 39.1% of the cohort.

The most common associated comorbidities in nonvalvular AF were hypertension (48%), obesity or overweight (53.4%), diabetes (22.6%), and congestive heart failure (12.7%).

In nonvalvular AF, the mean CHA<sub>2</sub>DS<sub>2</sub>VASc score was  $2.4 \pm 1.6$  with 12.3% having CHA<sub>2</sub>DS<sub>2</sub>VASc score 0, 20.1% having CHA<sub>2</sub>DS<sub>2</sub>VASc score 1, and 67.6% having CHA<sub>2</sub>DS<sub>2</sub>VASc score  $\geq 2$  (Table 1). The mean HAS-BLED score was  $1.4 \pm 1.1$ .

Table 1 summarizes the main characteristics of the population.

### 3.2 | Use of antithrombotic agents and quality of anticoagulation (TTR)

Six hundred forty four patients (70.38%) were taking anticoagulants, predominantly acenocoumarol. New oral anticoagulant drugs (NOAC) were used in only three patients. Antiplatelet agents alone were given to 126 patients (13.8%) and in combination with anticoagulants to 54 patients, accounting for 5.9% of the cohort. Among the patients, 199 (21.7%) had no antithrombotic therapy. Fifty-three out of 205 patients with valvular AF (25.85%) had no antithrombotic therapy (36 patients) or received antiplatelet drugs (17 patients) (Figure 1).

In the group of nonvalvular AF, for patients with CHA<sub>2</sub>DS<sub>2</sub>VASc score zero (245 patients), oral anticoagulants were used in 136 patients (55.5%), antiplatelet therapy alone was prescribed in

23 patients (9.4%), and 86 patients (35.1%) did not have any anti-thrombotic therapy (Figure 1). In patients with score CHA<sub>2</sub>DS<sub>2</sub>VASc  $\geq 2$  (216 patients), 82.9% (179 patients) of them received anticoagulants. Seven percent (15 patients) received antiplatelet therapy alone and 10.2% (22 patients) did not have any antithrombotic therapy.

The proportions of antithrombotic use according to CHA<sub>2</sub>DS<sub>2</sub>VASc score in nonvalvular AF are shown in Figure 1.

The mean TTR with the Rosendaal method, obtained in 341 patients was  $48.87 \pm 28.69\%$ . Only 110 patients (32.25%) had an adequate level of anticoagulation (TTR  $\geq 65\%$ ).

None of the cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia, and smoking) was significantly associated with TTR (Table 2). For patients with nonvalvular AF, none of CHA<sub>2</sub>DS<sub>2</sub>VASc score, HAS-BLED score, or SAMe-TT2R2 score was significantly associated with the quality of anticoagulation (TTR  $\geq 65\%$ ).

After multivariate adjustment (Table 2), the variables significantly associated with poor anticoagulation level were congestive heart failure (Adjusted OR equal to 0.23, 95% CI: 0.065–0.876), and non-valvular AF type (Adjusted OR: 0.24, 95% CI: 0.134–0.435).


However, prescription of antiplatelet therapy was associated with an adequate anticoagulation therapy (TTR  $\geq 65\%$ ) (Adjusted OR equal to 3.599, 95% CI: 1.249–10.373).

During follow-up, 31 patients stopped anticoagulant drugs. The reasons for discontinuation were related to the patients' non-adherence in 32.3% of the cases and to the physicians' decision in 67.8% of the cases (physician preference in 45.2% of the cases and contraindication to anticoagulant in 22.6% of the patients).

### 3.3 | Rate and rhythm control

Rate control was attempted in 48.4% of AF patients with the use of beta-blockers, digoxin, and calcium blockers in respectively 59.9%, 29.9%, and 20.3% of the patients.

The most often prescribed antiarrhythmic drugs (AADs) were amiodarone (52.6%), flecainide (8.7%), and sotalol (3.3%). Catheter ablation was only attempted in 0.4% of the overall population. Pacemaker implantation was performed in 3.9% of the whole cohort.



**FIGURE 1** Distribution of Antithrombotic drug use in valvular and nonvalvular AF patients according to CHA<sub>2</sub>DS<sub>2</sub>VASc score

**TABLE 2** Predictive factors for obtaining a correct time in therapeutic range for patients under coumarins (multivariable analysis)

	OR (95% CI)	p
Age	1.011 (0.981; 1.042)	.476
Dyslipidemia	1.345 (0.651; 2.777)	.424
Diabetes	1.484 (0.555; 3.965)	.432
Smoking	0.612 (0.22; 1.706)	.348
<b>CHF</b>	0.239 (0.065; 0.876)	<b>.031</b>
OSA	1.187 (0.209; 6.73)	.847
CHA <sub>2</sub> DS <sub>2</sub> VASc risk score	0.925 (0.471; 1.819)	.822
Hypertension	0.895 (0.348; 2.299)	.818
LVEF	0.996 (0.969; 1.023)	.745
<b>AP</b>	3.599 (1.249; 10.373)	<b>.018</b>
Cancer	0.343 (0.041; 2.848)	.322
BMI	0.972 (0.919; 1.027)	.306
Male gender	0.965 (0.469; 1.984)	.923
History of ischemic stroke	1.322 (0.507; 3.448)	.568
<b>Nonvalvular AF</b>	0.241 (0.134; 0.435)	<b>&lt;.001</b>
SAMe-TT2R2 score	1.2 (0.464; 3.106)	.707

Abbreviations: AP: antiplatelet, BMI: body mass index, CHF: congestive heart failure, 95% CI: 95% Confidence Interval, LVEF: left ventricular ejection fraction, OR: Odds-ratio, OSA: obstructive sleep apnea.

### 3.4 | Outcomes at 12 months

During the 12-month follow-up period, 15 patients showed thromboembolic complications (1.64%), among them two patients were not receiving anticoagulation therapy. Stroke represented 53.3% of these complications. After multivariate adjustment (Table 3), the variables significantly associated with thromboembolic complications were obstructive sleep apnea (Adjusted OR equal to 42.486, 95% CI: 4.21–428.781, *p* = .001), and higher CHA<sub>2</sub>DS<sub>2</sub>VASc score (Adjusted OR equal to 4.631, 95% CI: 1.135–18.886, *p* = .033).

Bleeding occurred in 53 patients (5.8%). Cerebral hemorrhage and digestive bleeding were reported during the follow-up, respectively in 0.5 and 1% of all AF patients. Hypertension (Adjusted OR equal to 4.027, 95% CI: 1.065–15.227, *p* = .04) and antiplatelet drug use (Adjusted OR equal to 4.659, 95% CI: 1.509–14.381, *p* = .007) were associated with bleeding complications (Table 3).

During follow-up, 52 patients died (5.6%) (Figure 2). Cardiovascular death occurred in 38 patients (4.1%). The predictive factors for cardiovascular death were congestive heart failure (Adjusted OR equal to 3.821, 95% CI: 1.377–10.607, *p* = .01), and hypertension (Adjusted OR equal to 0.374, 95% CI: 0.108–1.291, *p* = .01).

## 4 | DISCUSSION

NATURE-AF is the first large scale prospective registry assessing the epidemiological characteristics, management, and outcomes in North African patients with recently documented atrial fibrillation by both private and public cardiologists. First, valvular AF was still prevalent (22.4%) despite the demographic transition in the region. Second, the quality of anticoagulation was still poor and adherence to guidelines was not optimal. Third, Rhythm control was attempted in 48.4% of the patients and only four of them had catheter ablation. Finally, thromboembolic, bleeding, and cardiovascular death occurred in 1.64%, 5.8%, and 5.7% of the patients respectively, during the one-year follow-up period.

This registry provides interesting data allowing to compare treatment and response variation among AF populations in Africa and to evaluate adherence to recent guidelines.


### 4.1 | Clinical characteristics

Our population was younger and characterized by more prevalence of women and valvular AF compared to non-African AF (occidental)

**TABLE 3** Predictive factors for thromboembolic and bleeding complications and cardiovascular death (Multivariable analysis)

	Thromboembolic complications adjusted OR (95% CI)	Bleeding complications adjusted OR (95% CI)	Cardiovascular death adjusted OR (95% CI)
Age	0.985 (0.923; 1.052)	0.991 (0.952; 1.031)	0.997 (0.955; 1.04)
Dyslipidemia	0.232 (0.015; 3.595)	1.12 (0.409; 3.062)	0.949 (0.32; 2.814)
Diabetes mellitus	0.1 (0.009; 1.141)	0.936 (0.218; 4.016)	0.457 (0.125; 1.674)
Smoking habit	0.861 (0.084; 8.849)	0.894 (0.309; 2.59)	1.224 (0.406; 3.692)
Congestive heart failure	2.348 (0.377; 14.624)	0.496 (0.103; 2.38)	<b>3.821 (1.377; 10.607)#</b>
Obstructive sleep apnea	<b>42.486 (4.21; 428.781)*</b>	1.619 (0.254; 10.319)	
Mean CHA <sub>2</sub> DS <sub>2</sub> VASc score	<b>4.631 (1.135; 18.886)**</b>	0.626 (0.228; 1.719)	3.147 (1.32; 7.5)
Hypertension	0.435 (0.056; 3.392)	<b>4.027 (1.065; 15.227)§</b>	<b>0.374 (0.108; 1.291)#</b>
LVEF	0.998 (0.931; 1.069)	0.991 (0.953; 1.03)	1.024 (0.984; 1.066)
Oral Anticoagulant drugs	0.533 (0.078; 3.659)	2.367 (0.657; 8.527)	1.506 (0.458; 4.947)
Antiplatelet drugs	0.699 (0.085; 5.748)	<b>4.659 (1.509; 14.381)§§</b>	1.83 (0.577; 5.804)
Respiratory failure	0.807 (0.073; 8.88)	1.487 (0.35; 6.31)	0.741 (0.153; 3.579)
Cancer	4.266 (0.223; 81.65)	2.682 (0.515; 13.972)	2.954 (0.459; 19.022)
Body mass index	0.84 (0.704; 1.002)	0.965 (0.889; 1.047)	0.943 (0.862; 1.031)
Coronary artery disease	2.324 (0.211; 25.632)	0.656 (0.137; 3.147)	1.446 (0.427; 4.892)
Gender (Male)	0.715 (0.154; 3.331)	0.721 (0.304; 1.709)	0.826 (0.329; 2.071)

Note: \* $p = .001$ ; \*\* $p = .033$ ; § $p = .04$ ; §§ $p = .007$ ; # $p = .01$ . Adjusted OR: Adjusted Odds-ratio, 95% CI: 95% Confidence Interval.

**FIGURE 2** Kaplan–Meier plot: Thromboembolic complications (Panel A), Bleeding complications (Panel B) and death (Panel C) during follow-up (survival in weeks (Moy, IC 95%) 62.4 [59.6–65.3])

registries.<sup>12–14</sup> In nonvalvular AF patients, the stroke risk score was lower than in ORBIT-AF,<sup>14</sup> GLORIA,<sup>15</sup> GARFIELD,<sup>16</sup> and PREFER<sup>17</sup> registries (mean CHADSVASC score  $2.4 \pm 1.6$ ).

Only two published studies describing the epidemiological data in Tunisia are available.<sup>5,7,18</sup> In 2003, Drissa et al<sup>5</sup> conducted a multicenter study involving 1134 patients presenting with a first episode of AF between January 1985 and December 2000. The average age was 58.6 (15–60) years, and 656 patients (57.8%) were males. The most common identified etiology of AF was rheumatic carditis (36.1%). Higher morbidity and mortality were demonstrated in AF patients with a 5-year survival rate of 85%.

Thus, a decrease in the prevalence of valvular atrial fibrillation and an increase in the prevalence of nonvalvular atrial fibrillation with a high prevalence of hypertension, congestive heart failure, and diabetes were noted in NATURE-AF. This is in accordance with the epidemiological transition seen in North Africa.

## 4.2 | Antithrombotic AF management

In a recent review, Mazurek et al<sup>19</sup> demonstrated that despite the differences in design and methodology between a wide variety of registries on AF in European, North American, and Asian populations, there are apparent regional differences and gaps in stroke prevention, with approximately one third of AF patients not being treated in accordance with guidelines.<sup>20</sup>

In our registry, 64.8% of low-risk stroke patients received anticoagulants and/or antiplatelet therapy. In valvular AF patients and high-risk stroke nonvalvular AF patients, 25.9% and 17.1% had no anticoagulant therapy or antiplatelet therapy, respectively.

Acenocoumarol remains the most prescribed anticoagulant (99% of the total anticoagulants prescribed in NATURE-AF). Direct oral anticoagulants were not available in Tunisia during the inclusion and the follow-up period of the registry. Currently, direct oral anticoagulants

are gradually replacing vitamin K antagonist in both Europe and North America.<sup>21</sup>

Among REALIZE-AF patients with a CHADS<sub>2</sub> score  $\geq 2$ , there are also important geographical differences with respect to the use of antithrombotic agents. In fact, the proportion of patients not receiving antithrombotic therapy ranges from 11.4% in the Middle East and Africa to 27.6% in Latin America. Conversely, the use of oral anticoagulants is the highest in the Middle East and Africa (66.7%) and the lowest in Asia (31.7%).<sup>7,18</sup>

Despite efforts, adherence to thromboprophylaxis guidelines in NATURE-AF was still suboptimal. This was also noticed in other registries as approximately half of truly low-risk patients are over-treated with oral anticoagulation, and one third of high-risk patients are not anticoagulated.<sup>12,15,22</sup>

In NATURE-AF, the quality of anticoagulation was still poor, with a mean TTR of  $48.87 \pm 28.69$  and a low rate of adequate quality of anticoagulation (TTR  $> 65\%$ ) observed in 32.3% of the patients. The same results were obtained in a recent study published in Tunisia.<sup>23</sup>

In the J RHYTHM Registry, despite an overall high oral anticoagulation of 87.3%, only 53% of the patients met the target international normalized ratio levels.<sup>24</sup>

### 4.3 | Rate versus rhythm management

Of the two main strategies for the treatment of AF, the 'rate control' and 'rhythm control' were similarly chosen in our registry. In REALIZE-AF,<sup>25</sup> the rhythm control was the most commonly chosen strategy (57.5% vs. 37.2%).

Regarding the rate control drugs, beta-blockers and non-dihydropyridine calcium channel blockers were more often used than digoxin in NATURE-AF. Amiodarone was the most common antiarrhythmic drug used (36%). The low rate of catheter AF ablation is mainly due to economic reasons. In fact, in North African countries, costs of catheter AF ablation are borne by the patient rather than a health insurance.

In the ReLY-AF registry,<sup>8</sup> beta-Blockers were prescribed in 41.8% of the patients, ranging from 21.7% in Africa to half of the patients in North America and Western as well as Eastern Europe. A quarter of the patients received digoxin, ranging from 12.7% in Western Europe to more than one-third of the patients in India and Africa. In total, 8.2% of the patients were treated with verapamil or diltiazem, with only 2.0% in Africa and up to 18.5% in North America. Amiodarone was the most specific antiarrhythmic drug used in 8.7% of the patients, with a large variation from  $\leq 5\%$  in North America, Western Europe, the Middle East, and Africa to  $>5\%$  in South America, and Eastern Europe. In EORAP-AF pilot registry,<sup>26</sup> amiodarone was the most commonly used antiarrhythmic drug (21.5%), followed by sodium channel blockers. In the EURO HEART SURVEY (EHS),<sup>27</sup> like in AFNET<sup>28</sup> and in PREFER<sup>17</sup> registries, one third of the patients received class III antiarrhythmic agents.

## 4.4 | Outcomes

AF remains a major cause of morbidity and mortality. At 1 year, cardiovascular mortality was estimated to be 5.7% and thromboembolic complications to be 1.6% in this registry. These results were similar to EORP-AF pilot registry<sup>26</sup> and EHS,<sup>29</sup> where mortality was estimated to be 5.7% and 5.3%, respectively. The thromboembolic complications rate was similar to that revealed in EHS (1.8%) but higher than that shown in EOARP-AF stroke complications.<sup>21,26,29</sup>

## 4.5 | Limitations

Our data should be interpreted in the context of their limitations. In fact, this study was conducted by only 92 private and public cardiologists who accepted to participate in this registry. Only patients who consented to the study were enrolled. Therefore, not all new documented AF patients were involved, particularly those who presented to first care medical centers (noncardiologists). The follow-up period extended over only 1 year; thus, a long term follow-up is required.

## 5 | SUMMARY

These data have important clinical and public health implications for North African populations, who are in an epidemiological transition.

Valvular AF was present in one-fifth of Tunisian patients. Almost half of the registered nonvalvular AF patients were at low risk of stroke and had a high rate of acenoucoumarol use. However, the quality of anticoagulation was poor and compliance with the treatment guidelines remained suboptimal. Despite the low economic resources, health policy should enhance educational strategies, screening, management, and prevention strategies, in addition to new medication and technologies, such as catheter AF ablation and the use of direct oral anticoagulants to improve AF management and to offer better risk benefit ratios. These results highlight the need for a strategy that might have particular advantages for middle-income North African countries, having limited resources.

### ACKNOWLEDGMENT

We thank the trial investigators and coordinators at all the centers, the trial monitors and staff from the DACIMA, Rabie Razgallah MD for assistance with biostatistics, and the participating patients for their contribution to the trial.

### CONFLICT OF INTEREST

The authors declare no potential conflict of interests.

### AUTHOR CONTRIBUTIONS

The manuscript has been read and approved by all the authors.

## ETHICS STATEMENT

Ethics approval was applicable and a written informed consent was obtained from the participants in the study.

## DATA AVAILABILITY STATEMENT

Data supporting the findings of this study are available on request from the corresponding author.

## ORCID

Sana Ouali  <https://orcid.org/0000-0001-7427-4926>

## REFERENCES

1. Stambler BS, Ngunga LM. Atrial fibrillation in sub-Saharan Africa: epidemiology, unmet needs, and treatment options. *Int J Gen Med*. 2015; 8:231-242.
2. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. *Nat Rev Cardiol*. 2014;11:639-654.
3. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. *Clin Epidemiol*. 2011;3: 67-84.
4. Rothenbühler M, O'Sullivan CJ, Stortecky S, et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. *Lancet Glob Health*. 2014;2:e717-e726.
5. Drissa H, Essafi N, Mahjoub H, et al. Multicenter study of atrial fibrillation. *Tunis Med*. 2003;81(Suppl 8):625-631.
6. Sliwa K, Carrington MJ, Klug E, et al. Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the heart of Soweto study. *Heart*. 2010;96: 1878-1882.
7. Gamra H, Murin J, Chiang CE, Naditch-Brülé L, Brette S, Steg PG. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the international Realise AF survey. *Arch Cardiovasc Dis*. 2014;107:77-87.
8. Sani MU, Davison BA, Cotter G, et al. Prevalence, clinical characteristics and outcomes of valvular atrial fibrillation in a cohort of African patients with acute heart failure: insights from the THESUS-HF registry. *Cardiovasc J Afr*. 2018;29:139-145.
9. Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY atrial fibrillation registry. *Circulation*. 2014;129:1568-1576.
10. Ben Halima A, Ouali S, Mourali MS, Chabrak S, Chettaoui R, Ben Halima M, et al. Design and rationale of the National Tunisian Registry of atrial fibrillation: protocol for a prospective. *Multicenter Trial JMIR Res Protoc*. 2018;7:e181.
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost*. 1993;69:236-239.
12. Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational research Programme atrial fibrillation (EORP-AF) pilot general registry. *Europace*. 2014;16: 308-319.
13. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation—The J-RHYTHM Registry study design. *J Cardiol*. 2011;57:95-99.
14. Fosbol EL, Holmes DN, Piccini JP, et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. *J Am Heart Assoc*. 2013;2: e000110.
15. Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry, phase II. *Am J Med*. 2015;128: 1306.e1-1313.e1.
16. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: global anticoagulant registry in the FIELD(GARFIELD). *Am Heart J*. 2012;163: 13-19.
17. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the prevention of thromboembolic events—European registry in atrial fibrillation (PREFER in AF). *Europace*. 2014;16:6-14.
18. Chiang CE, Naditch-Brülé L, Brette S, et al. Atrial fibrillation management strategies in routine clinical practice: insights from the international Realise AF survey. *PLoS One*. 2016;11:e0147536.
19. Mazurek M, Huisman MV, Lip GYH. Registries in atrial fibrillation: from trials to real-life clinical practice. *Am J Med*. 2017;130:135-145.
20. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893-2962.
21. Lip GYH, Laroche C, Popescu MI, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF general pilot registry. *Europace*. 2015;17:1777-1786.
22. De Caterina R, Ammentorp B, Darius H, et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. *Heart*. 2014;100:1625-1635.
23. Ouali S, Mechri M, Ben Ali Z, et al. Factors associated to adequate time in therapeutic range with oral vitamin K antagonists in Tunisia. *Tunis Med*. 2019;97(1):113-121.
24. Inoue H, Okumura K, Atarashi H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM registry. *Circ J*. 2013;77:2264-2270.
25. Alam M, Bandeali SJ, Shahzad SA, Lakkis N. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. *Expert Rev Cardiovasc Ther*. 2012; 10:283-291.
26. Lip GYH, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational research Programme atrial fibrillation general registry pilot phase (EORP-AF pilot registry). *Eur Heart J*. 2014;35:3365-3376.
27. Nieuwlaet R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation. *Eur Heart J*. 2005;26:2422-2434.
28. Nabauer M, Gerth A, Limbourg T, et al. The registry of the German competence network on atrial fibrillation: patient characteristics and initial management. *Europace*. 2009;11:423-434.
29. Nieuwlaet R, Prins MH, Le Heuzey J-Y, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro heart survey on atrial fibrillation. *Eur Heart J*. 2008;29:1181-1189.

**How to cite this article:** Ouali S, Ben Halima A, Chabrak S, et al. Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF). *Clin Cardiol*. 2021;1-10. <https://doi.org/10.1002/clc.23558>